TruTechnologies rebrands to push real-time trial oversight

TruTechnologies has unveiled a new brand identity and updated website as it seeks to align itself with a broader push to modernise clinical trial execution.

The rebrand comes amid growing attention from US regulators and health officials on the pace and structure of drug development. TruTechnologies pointed to the Food and Drug Administration's real-time clinical trials pilot programme and the Department of Health and Human Services' Operation TrialBlazer as signs of stronger institutional support for changes in how trials are run and monitored.

Founded in 2018, TruTechnologies develops software designed to give sponsors and clinical sites a live view of trial activity at the point of care. Its main product, TruLab, is used at more than 3,300 clinical sites across 60 countries, according to the company.

The company argues that long-standing clinical development processes still leave sponsors with limited visibility into activity at site level. It says that can slow problem detection, delay decisions and lengthen study timelines.

Industry backdrop

Clinical trial reform has become a more prominent theme across the pharmaceutical sector as companies and regulators look for ways to cut delays and improve the flow of information. TruTechnologies argues that conventional trial systems often do not surface important data until days or weeks after it is first recorded, even when vendors describe those systems as operating in real time.

Its platform is built around what it calls live data capture and protocol-guided workflows on mobile devices. The aim is to make data available as it is captured and prevent out-of-protocol actions before they happen.

TruTechnologies says sponsors can monitor trial execution at site level through live-streamed data, allowing issues to be identified as they emerge rather than after later entry into electronic systems. The approach reflects a broader trend in life sciences towards earlier intervention in operational problems and closer oversight of study conduct.

Growth claims

The rebrand comes during a period of expansion. TruTechnologies says it has received a strategic investment from LLR Partners and expanded adoption of TruLab among pharmaceutical and biotechnology customers.

According to the company, the software has delivered up to a 97% reduction in source data errors, a 98% reduction in sample-related queries, and an 85% reduction in sponsor time spent on sample tracking. It also says the platform has the potential to cut time to market by up to three months.

Those figures underscore the commercial case technology suppliers are making in the clinical research market, where sponsors face pressure to shorten development timelines while maintaining confidence in trial data. Better visibility into sample handling, protocol adherence and data collection has become a central selling point for companies operating in this segment.

TruTechnologies says the new identity is intended to reflect both the urgency of industry change and its own position in that shift. The company has framed its message around the idea that clinical trial execution needs more fundamental redesign, rather than incremental improvements to legacy systems.

In comments released alongside the announcement, the leadership team tied the visual refresh directly to that view of the market.

"Our refreshed brand identity isn't just a new logo and website; it's part of our broader commitment to shepherd the industry into a new era of live, truly real-time clinical trial oversight," said Scott Ogle, Chief Executive Officer and Co-Founder of TruTechnologies. "Our new look and feel is rooted in the exact simplicity we are bringing to sites and sponsors each day and is aligned with the sense of urgency we are seeing from the industry at large for faster, clearer, and more confident clinical trial execution."

Ogle's comments place the rebrand within a wider effort to sharpen the company's profile as demand grows for software that can monitor trial conduct more directly. The market for digital clinical operations tools has become increasingly crowded, with vendors competing on speed of data access, site usability and oversight of protocol compliance.

Board leadership also presented the move as part of a broader effort to challenge older approaches in the sector.

"I often liken clinical trial modernization to a 60-year-old home, badly in need of updating. At TruTechnologies, we don't believe in patchwork renovations, but instead feel strongly that we need to fix clinical trial execution from the foundation," said Dr. Richard Graham, Chairman of the Board and Co-Founder of TruTechnologies. "Our new brand identity reflects the spirit of our team and technology, which represents a fearlessness to break free from legacy clinical trial inefficiencies."